Abstract
Finding a biomarker that predicts in-hospital adverse outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI), particularly progression to death and acute heart failure, has been always a subject of research. The aim of this study is to evaluate the usefulness of Cystatin
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
